Publications by authors named "Jonas Hallen"

Claim this Profile
D
Development of CAL101-a humanized monoclonal antibody targeting S100A4 to inhibit proinflammatory and profibrotic signaling.
Signe Vedel Borchert, Jonas Hallén, Rizwan Iqbal Hussain, Ian Holyer, Jesper T Troelsen

J Pharmacol Exp Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply.
Jörg H W Distler, Jonas Hallén

Arthritis Rheumatol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Anti-S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis-Specific Transcriptional Signatures in Human Skin.
Thuong Trinh-Minh, Andrea-Hermina Györfi, Michal Tomcik, Cuong Tran-Manh, Xiang Zhou

Arthritis Rheumatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin.
Xiao Švec, Hana Štorkánová, Thuong Trinh-Minh, Manh Cuong Tran, Lenka Štorkánová

Rheumatology (Oxford)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis.
Christopher P Denton, Shiwen Xu, Fenge Zhang, Rory H Maclean, Kristina E N Clark

Ann Rheum Dis· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014-2020.
Kristina Malene Ødegaard, Sandre Svatun Lirhus, Hans Olav Melberg, Jonas Hallén, Sigrun Halvorsen

ESC Heart Fail· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nationwide registry study on heart failure in Norway from 2008 to 2018: variations in lookback period affect incidence estimates.
Kristina Malene Ødegaard, Sandre Svatun Lirhus, Hans Olav Melberg, Jonas Hallén, Sigrun Halvorsen

BMC Cardiovasc Disord· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016.
Kristina Malene Ødegaard, Jonas Hallén, Sandre Svatun Lirhus, Hans Olav Melberg, Sigrun Halvorsen

ESC Heart Fail· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial.
Jonas Hallén, Aldo P Maggioni, Esteban Lopez-De-Sa, Fabio M Turazza, Klaus Witte

Eur J Heart Fail· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.
Aldo P Maggioni, José López-Sendón, Olav W Nielsen, Jonas Hallén, Maryam Aalamian-Mattheis

Eur J Heart Fail· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations.
Jonas Hallén, Nadarajah Sreeharan

Eur Heart J Cardiovasc Pharmacother· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increases in Circulating Cardiac Troponin Are Not Always Associated with Myocardial Cell Death.
Solve Tjora, Trygve S Hall, Anne C Larstorp, Jonas Hallen, Dan Atar

Clin Lab· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.
John J P Kastelein, Jonas Hallén, Runar Vige, David A Fraser, Rong Zhou

Cardiology· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.
Harold E Bays, Jonas Hallén, Runar Vige, David Fraser, Rong Zhou

J Clin Lipidol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Trygve Sørdahl Hall, Jonas Hallén, Mitchell W Krucoff, Matthew T Roe, Danielle M Brennan

Am Heart J· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid-related protein-8/14 and C-reactive protein in individuals evaluated for obstructive sleep apnea.
Trygve Sørdahl Hall, Tobias Erik Herrscher, Petr Jarolim, Morten Wang Fagerland, Torstein Jensen

Sleep Med· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obstructive sleep apnea: no independent association to troponins.
Trygve Sørdahl Hall, Tobias Herrscher, Petr Jarolim, Morten W Fagerland, Torstein Jensen

Sleep Breath· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty.
Wiktor Kuliczkowski, Joanna Urbaniak, Jonas Hallén, Mieczysław Woźniak, Lech Poloński

Kardiol Pol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in diagnosing non-ST-segment elevation myocardial infarction after the introduction of a new high-sensitivity cardiac troponin T assay: a single-centre experience.
Trygve Sørdahl Hall, Jonas Hallén, Stefan Agewall, Dan Atar, Torstein Jensen

Clin Lab· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Troponin for the estimation of infarct size: what have we learned?
Jonas Hallén

Cardiology· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction.
Lennart Nilsson, Jonas Hallén, Dan Atar, Lena Jonasson, Eva Swahn

Heart· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.
Victor L Serebruany, Michael Miller, Alex N Pokov, Donald Lynch, Jesper K Jensen

Cardiology· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activated leukocyte cell adhesion molecule and prognosis in acute ischemic stroke.
Linda Smedbakken, Jesper K Jensen, Jonas Hallén, Dan Atar, James L Januzzi

Stroke· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relation of cardiac troponin I and microvascular obstruction following ST-elevation myocardial infarction.
Jonas Hallén, Jesper K Jensen, Peter Buser, Allan S Jaffe, Dan Atar

Acute Card Care· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Troponin I degradation in serum of patients with acute ischemic stroke.
Jesper K Jensen, Jonas Hallén, Terje Lund, Lene Helleskov Madsen, Zanina Grieg

Scand J Clin Lab Invest· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis